Skip to main content

Table 5 Comparison serum profiles PR vs. no PR

From: Prediction of outcome of non-small cell lung cancer patients treated with chemotherapy and bortezomib by time-course MALDI-TOF-MS serum peptide profiling

m/z p-value
2215.2849 0.0083178
2009.0039 0.015663
2318.2202 0.032445
2378.1982 0.042583
900.4258 0.048584
  1. Five peaks were significantly differential comparing NSCLC patients with a partial response versus patients with stable or progressive disease. None of the 5 peptides were positively identified. Ordered by p-value.